Cargando…

Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database

Background: Reports were recently published on hepatitis B virus reactivation (HBVr), tuberculosis (TB), and atypical mycobacterial infection (AMI) in patients with ustekinumab treatment. However, the literature is limited to case reports and series. The study was aimed to investigate their relation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jingjing, Geng, Xiaozhen, Zhang, Xin, Xiao, Yanfeng, Wang, Wenjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289361/ https://www.ncbi.nlm.nih.gov/pubmed/35860015 http://dx.doi.org/10.3389/fphar.2022.921084

Ejemplares similares

Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases
por: Wang, Jingjing, et al.
Publicado: (2022)

Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database
por: Wang, Shuai, et al.
Publicado: (2020)

Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021)

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database
por: Wan, Qing, et al.
Publicado: (2022)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
por: Ceschi, Alessandro, et al.
Publicado: (2020)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow)
por: Barbosa, Luiza Hoehl Loureiro Alves, et al.
Publicado: (2022)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
por: Liu, Leping, et al.
Publicado: (2023)

An update on the Pharmacovigilance Programme of India
por: Lihite, Ratan J., et al.
Publicado: (2015)

Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study
por: Deng, Zhenzhen, et al.
Publicado: (2023)

Associations of Epstein-Barr Virus Infection with Attention Deficit Hyperactivity Disorder, Learning Disability, and Special Education in US Children
por: Wang, Jingjing, et al.
Publicado: (2022)

Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions
por: Karapetiantz, Pierre, et al.
Publicado: (2018)

Propensity Score-Based Approaches in High Dimension for Pharmacovigilance Signal Detection: an Empirical Comparison on the French Spontaneous Reporting Database
por: Courtois, Émeline, et al.
Publicado: (2018)

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
por: Gozzo, Lucia, et al.
Publicado: (2021)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
por: Shu, Yamin, et al.
Publicado: (2022)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
por: Zhou, Shuang, et al.
Publicado: (2022)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
por: Li, Huixia, et al.
Publicado: (2023)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study
por: Pozsgai, Kevin, et al.
Publicado: (2022)

Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis
por: Chen, Congqin, et al.
Publicado: (2023)

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
por: Gao, Lei, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Editorial: Leveraging pharmacovigilance data mining with “the patient” in mind
por: Gossell-Williams, Maxine, et al.
Publicado: (2022)

Editorial: Reducing the Harm of Medication–Recent Trends in Pharmacovigilance
por: Ramírez, Elena, et al.
Publicado: (2022)

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies
por: Bromley, R. L., et al.
Publicado: (2023)

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
por: Noguchi, Yoshihiro, et al.
Publicado: (2023)

Pharmacovigilance Bibliometrics: Visualizing Thematic Development in the Category of Pharmacology and Pharmacy in Web of Science
por: Wang, Li, et al.
Publicado: (2021)

Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
por: Wang, Chengcheng, et al.
Publicado: (2023)

Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database – A Case Study
por: Gaio, Mario, et al.
Publicado: (2021)

The Role of an Interventional Program for Improving Pharmacovigilance at a Pediatric Facility
por: Kronenfeld, Nirit, et al.
Publicado: (2019)

Safety of Inulin and Sinistrin: Combining Several Sources for Pharmacovigilance Purposes
por: Bui, T-V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_foqkagluphddh2hibjvol2pkv8